ArticleNucleic acids research2026
m6AConquer: a consistently quantified and orthogonally validated database for the N6-methyladenosine (m6A) epitranscriptome.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC.Science advances · 2026Article
- Decoding causal m6A: a bioinformatics roadmap for psychiatric disorders.Briefings in bioinformatics · 2026Review
- Stoichiometry-preserving and stochasticity-aware identification of m6A from direct RNA sequencing.Briefings in bioinformatics · 2026Article
- mRNA processing in cancer immunotherapy: emerging targets, resistance mechanisms, and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The proper placement of N6-methyladenosine (m6A) on mRNA is essential for normal cell function, and its disruption is linked to numerous human diseases. The rapid growth of m6A data from diverse sequencing technologies presents challenges for integrative analysis due to technique-specific biases and inconsistent processing. While existing databases provide valuable catalogs, their reliance on aggregating pre-processed results can propagate inconsistencies. To overcome these limitations, we present m6AConquer, a database founded on reproducible quantification. We systematically re-processed raw data from 10 distinct profiling methods, including high-resolution GLORI and eTAM-seq, quantifying methylation at millions of consensus sites across human and mouse. Our rigorous pipeline features uniform site-calling and false-positive calibration with in vitro transcribed (IVT) controls where available. By leveraging a reproducibility-based framework across technically orthogonal methods, we identified over 135300 orthogonally validated m6A sites in human (IDR < 0.05). Beyond this validated methylome, m6AConquer provides matched multi-omics data (gene expression, splicing, variants) and identifies m6A quantitative trait loci (m6A QTLs) to link RNA modification to genetic regulation and disease. Offering intuitive query tools, interactive visualizations, and downloadable, analysis-ready data matrices, m6AConquer provides a standardized resource for rigorous exploration of the roles of m6A in biology and medicine, freely accessible at https://rnamd.org/m6aconquer/.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.